-
-
-
-
-
-
-
Amneal Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Amneal to Report First Quarter 2026 Results on May 1, 2026
-
-
-
-
-
-
-
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®
-
-
-
-
-
-
-
Amneal receives FDA approval for generic RESTASIS eye drops
-
-
-
-
-
-
-
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
-
-
-
-
-
-
-
Amneal gets FDA approval for generic sodium oxybate oral solution
-
-
-
-
-
-
-
Amneal seeks $1.8 billion term loan and $750 million bond offering
-
1,199,634 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

